Mastocytosis are myeloproliferative neoplasms commonly related to gain-of-function mutations involving the tyrosine kinase domain of KIT. We herein report a case of familial systemic mastocytosis with the rare KIT K509I germ line mutation affecting two family members: mother and daughter. In vitro treatment with imatinib, dasatinib and PKC412 reduced cell viability of primary mast cells harboring KIT K509I mutation. However, imatinib was more effective in inducing apoptosis of neoplastic mast cells. Both patients with familial systemic mastocytosis had remarkable hematological and skin improvement after three months of imatinib treatment, suggesting that it may be an effective front line therapy for patients harboring KIT K509I mutation.381012451251Garcia-Montero, A.C., Jara-Acevedo, M., Teodosio, C., Sanchez, M.L., Nunez, R., Prados, A., KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients (2006) Blood, 108, pp. 2366-2372Sanchez-Munoz, L., Alvarez-Twose, I., Garcia-Montero, A.C., Teodosio, C., Jara-Acevedo, M., Pedreira, C.E., Evaluation of the WHO criteria for the classification of patients with mastocytosis (2001) Mod Pathol, 24, pp. 1157-1168Valent, P., Horny, H.P., Escribano, L., Longley, B.J., Li, C.Y., Schwartz, L.B., Diagnostic criteria and classification of mastocytosis: a consensus proposal (2001) Leuk Res, 25, pp. 603-625Escribano, L., Akin, C., Castells, M., Orfao, A., Metcalfe, D.D., Mastocytosis: current concepts in diagnosis and treatment (2002) Ann Hematol, 81, pp. 677-690Valent, P., Akin, C., Sperr, W.R., Escribano, L., Arock, M., Horny, H.P., Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria (2003) Leuk Res, 27, pp. 635-641Horny, H., Metcalfe, D., Bennet, J., Bain, B., Akin, C., Escribano, L., Mastocytosis (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, pp. 54-63. , IARC Press, Lyon, S. Swerdlow, E. Campo, N. Harris, E. Jaffe, S. Pileri, H. Stein, J. Thiele, J. Vardiman (Eds.)Georgin-Lavialle, S., Lhermitte, L., Dubreuil, P., Chandesris, M.O., Hermine, O., Damaj, G., Mast cell leukemia (2013) Blood, 121, pp. 1285-1295Pardanani, A., Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management (2013) Am J Hematol, 88, pp. 612-624Fowler, J.F., Parsley, W.M., Cotter, P.G., Familial urticaria pigmentosa (1986) Arch Dermatol, 122, pp. 80-81Clark, D.P., Buescher, L., Havey, A., Familial urticaria pigmentosa (1990) Arch Intern Med, 150, pp. 1742-1744Oku, T., Hashizume, H., Yokote, R., Sano, T., Yamada, M., The familial occurrence of bullous mastocytosis (diffuse cutaneous mastocytosis) (1990) Arch Dermatol, 126, pp. 1478-1484Anstey, A., Lowe, D.G., Kirby, J.D., Horton, M.A., Familial mastocytosis: a clinical, immunophenotypic, light and electron microscopic study (1991) Br J Dermatol, 125, pp. 583-587Chang, A., Tung, R.C., Schlesinger, T., Bergfeld, W.F., Dijkstra, J., Kahn, T.A., Familial cutaneous mastocytosis (2001) Pediatr Dermatol, 18, pp. 271-276Hartmann, K., Wardelmann, E., Ma, Y., Merkelbach-Bruse, S., Preussner, L.M., Woolery, C., Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis (2005) Gastroenterology, 129, pp. 1042-1046Wasag, B., Niedoszytko, M., Piskorz, A., Lange, M., Renke, J., Jassem, E., Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis (2011) Exp Hematol, 39. , 859-65 e2Kunstlinger, H., Huss, S., Merkelbach-Bruse, S., Binot, E., Kleine, M.A., Loeser, H., Gastrointestinal Stromal tumors with KIT exon 9 mutations: update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing (2013) Am J Surg Pathol, 37, pp. 1648-1659Zanotti, R., Simioni, L., Garcia-Montero, A.C., Perbellini, O., Bonadonna, P., Caruso, B., Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis (2013) J Allergy Clin Immunol, 131, pp. 605-607Ning, Z.Q., Li, J., Arceci, R.J., Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells (2001) Blood, 97, pp. 3559-3567Rottapel, R., Reedijk, M., Williams, D.E., Lyman, S.D., Anderson, D.M., Pawson, T., The Steel/W transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor (1991) Mol Cell Biol, 11, pp. 3043-3051Linnekin, D., Early signaling pathways activated by c-Kit in hematopoietic cells (1999) Int J Biochem Cell Biol, 31, pp. 1053-1074Nagata, H., Worobec, A.S., Oh, C.K., Chowdhury, B.A., Tannenbaum, S., Suzuki, Y., Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder (1995) Proc Natl Acad Sci U S A, 92, pp. 10560-10564Akin, C., Brockow, K., D'Ambrosio, C., Kirshenbaum, A.S., Ma, Y., Longley, B.J., Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit (2003) Exp Hematol, 31, pp. 686-692Zermati, Y., De Sepulveda, P., Feger, F., Letard, S., Kersual, J., Casteran, N., Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms (2003) Oncogene, 22, pp. 660-664Ustun, C., DeRemer, D.L., Akin, C., Tyrosine kinase inhibitors in the treatment of systemic mastocytosis (2011) Leuk Res, 35, pp. 1143-1152Traina, F., Visconte, V., Jankowska, A.M., Makishima, H., O'Keefe, C.L., Elson, P., Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis (2012) PLoS ONE, 7, p. e43090Schwaab, J., Schnittger, S., Sotlar, K., Walz, C., Fabarius, A., Pfirrmann, M., Comprehensive mutational profiling in advanced systemic mastocytosis (2013) Blood, 122, pp. 2460-2466Traina, F., Carvalheira, J.B., Saad, M.J., Costa, F.F., Saad, S.T., BCR-ABL binds to IRS-1 and IRS-1 phosphorylation is inhibited by imatinib in K562 cells (2003) FEBS Lett, 535, pp. 17-22Akin, C., Escribano, L., Nuñez, R., Garcia-Montero, A., Angulo, M., Orfao, A., Well-differentiated systemic mastocytosis: a new disease variant with mature mast cell phenotype and lack of codon 816 c-Kit mutations (2004) J Allergy Clin Immunol, 113, p. S327Valent, P., Sotlar, K., Sperr, W.R., Escribano, L., Yavuz, S., Reiter, A., Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal (2014) Ann Oncol, , [Epub ahead of print]Zhang, L.Y., Smith, M.L., Schultheis, B., Fitzgibbon, J., Lister, T.A., Melo, J.V., A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy (2006) Leuk Res, 30, pp. 373-378Chan, E.C., Bai, Y., Kirshenbaum, A.S., Fischer, E.R., Simakova, O., Bandara, G., Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype (2014) J Allergy Clin Immunol, 134. , 178-87 e1Pagano, L., Valentini, C.G., Caira, M., Rondoni, M., Van Lint, M.T., Candoni, A., Advanced mast cell disease: an Italian Hematological Multicenter experience (2008) Int J Hematol, 88, pp. 483-488Schittenhelm, M.M., Shiraga, S., Schroeder, A., Corbin, A.S., Griffith, D., Lee, F.Y., Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies (2006) Cancer Res, 66, pp. 473-481Verstovsek, S., Tefferi, A., Cortes, J., O'Brien, S., Garcia-Manero, G., Pardanani, A., Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis (2008) Clin Cancer Res, 14, pp. 3906-3915Gleixner, K.V., Mayerhofer, M., Aichberger, K.J., Derdak, S., Sonneck, K., Bohm, A., PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects (2006) Blood, 107, pp. 752-759Feng, L.X., Ravindranath, N., Dym, M., Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia (2000) J Biol Chem, 275, pp. 25572-25576Growney, J.D., Clark, J.J., Adelsperger, J., Stone, R., Fabbro, D., Griffin, J.D., Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412 (2005) Blood, 106, pp. 721-724Roberts, K.G., Odell, A.F., Byrnes, E.M., Baleato, R.M., Griffith, R., Lyons, A.B., Resistance to c-KIT kinase inhibitors conferred by V654A mutation (2007) Mol Cancer Ther, 6, pp. 1159-1166